nature medicine t e c h n i c a l r e p o r t s A previous study reported the use of luminol for the detection of myeloperoxidase (MPO) activity using optical imaging in infiltrating neutrophils under inflammatory disease conditions. The detection is based on a photon-emitting reaction between luminol and an MPO metabolite. Because of tissue absorption and scattering, however, luminol-emitted blue light can be efficiently detected from superficial inflammatory foci only. In this study we report a chemiluminescence resonance energy transfer (CRET) methodology in which luminol-generated blue light excites nanoparticles to emit light in the near-infrared spectral range, resulting in remarkable improvement of MPO detectability in vivo. CRET caused a 37-fold increase in luminescence emission over luminol alone in detecting MPO activity in lung tissues after lipopolysaccharide challenge. We demonstrated a dependence of the chemiluminescent signal on MPO activity using MPO-deficient mice. In addition, co-administration of 4-aminobenzoic acid hydrazide (4-ABAH), an irreversible inhibitor of MPO, significantly attenuated luminescent emission from inflamed lungs. Inhibition of nitric oxide synthase with a nonspecific inhibitor, l-NAME, had no effect on luminol-mediated chemiluminescence production. Pretreatment of mice with MLN120B, a selective inhibitor of IKK-2, resulted in suppression of neutrophil infiltration to the lung tissues and reduction of MPO activity. We also demonstrated that CRET can effectively detect MPO activity at deep tissue tumor foci due to tumor development-associated neutrophil infiltration. We developed a sensitive MPO detection methodology that provides a means for visualizing and quantifying oxidative stress in deep tissue. This method is amenable to rapid evaluation of anti-inflammatory agents in animal models.
t e c h n i c a l r e p o r t s
A previous study reported the use of luminol for the detection of myeloperoxidase (MPO) activity using optical imaging in infiltrating neutrophils under inflammatory disease conditions. The detection is based on a photon-emitting reaction between luminol and an MPO metabolite. Because of tissue absorption and scattering, however, luminol-emitted blue light can be efficiently detected from superficial inflammatory foci only. In this study we report a chemiluminescence resonance energy transfer (CRET) methodology in which luminol-generated blue light excites nanoparticles to emit light in the near-infrared spectral range, resulting in remarkable improvement of MPO detectability in vivo. CRET caused a 37-fold increase in luminescence emission over luminol alone in detecting MPO activity in lung tissues after lipopolysaccharide challenge. We demonstrated a dependence of the chemiluminescent signal on MPO activity using MPO-deficient mice. In addition, co-administration of 4-aminobenzoic acid hydrazide (4-ABAH), an irreversible inhibitor of MPO, significantly attenuated luminescent emission from inflamed lungs. Inhibition of nitric oxide synthase with a nonspecific inhibitor, l-NAME, had no effect on luminol-mediated chemiluminescence production. Pretreatment of mice with MLN120B, a selective inhibitor of IKK-2, resulted in suppression of neutrophil infiltration to the lung tissues and reduction of MPO activity. We also demonstrated that CRET can effectively detect MPO activity at deep tissue tumor foci due to tumor development-associated neutrophil infiltration. We developed a sensitive MPO detection methodology that provides a means for visualizing and quantifying oxidative stress in deep tissue. This method is amenable to rapid evaluation of anti-inflammatory agents in animal models.
MPO is a heme-containing enzyme that is abundant in neutrophils and macrophages and functions as a key mediator of the phagocytic oxidative burst and inflammatory process 1 . MPO catalyzes the conversion of hydrogen peroxide and chloride ions into hypochlorous acid, which is one of the most reactive oxidants produced in vivo 2 . Hypochlorous acid oxidizes lipids, proteins and DNA and thus promotes tissue injury and inflammation 3 during the pathological progress of chronic obstructive pulmonary disease 4 (COPD) and atherosclerosis 5 . Circulating concentrations of MPO have been shown to predict risk for major adverse cardiac events. In addition, amounts of MPO-derived chlorinated compounds have been used as specific biomarkers for disease progression 6 . There has been considerable interest in the development of therapeutically useful MPO inhibitors. A previous study showed that 4-ABAH irreversibly inhibits hypochlorous acid production as a suicide substrate of MPO 7 . A means of monitoring MPO activity under in vivo conditions should help establish the relationship between MPO induction and pathological progression and facilitate preclinical evaluation of MPO inhibitors.
Noninvasive imaging of MPO enzymatic activity with luminol was previously reported 8 . These researchers found that luminol specifically interacts with hypochlorous acid to produce an emission of luminescent light that can be detected through optical imaging. When we applied luminol to several inflammatory disease models, we found that the detection was the most sensitive for superficially located inflammatory foci but was much less sensitive, and was undetectable in many cases, for deep tissue inflammation. A lack of sensitivity for the detection of deep tissue inflammation is the result of the poor penetration capability of luminol-emitted short-wavelength light (λ max = 425 nm) through animal tissues. It is well established that photons in the near-infrared (NIR) region (particularly 700-900 nm) are more penetrative through animal tissues because of reduced absorption and scattering 9 . We questioned whether NIR nanoparticles could be used to red shift luminol-emitted blue light to NIR, thus improving the in vivo detectability of MPO.
Previous work has established that luciferase or horseradish peroxidase conjugated to quantum dots allows luminescence to be absorbed and re-emitted by the nanoparticles, a phenomenon known as bioluminescence resonance energy transfer 10 (BRET) or CRET 11 . We hypothesized that luminescence energy transfer may also occur when the fluorescence acceptor is in a nonconjugated state. We tested this hypothesis by administering Luminol-R, a mixture of luminol and near-infrared quantum dots, to mice with induced lung inflammation or metastatic cancer. We demonstrate that luminol-emitted short-wavelength light can be red shifted by quantum dots through CRET, resulting in an increase in MPO detectability from deep-seated inflammatory foci. We show the utility of Luminol-R as a luminescent MPO readout and for evaluation of MPO inhibition under both in vitro and in vivo conditions.
RESULTS

Enhanced detection of MPO activity with quantum dots
To test whether quantum dots can be used to red shift luminolemitted blue light, we concomitantly administered luminol and 800-nm-emitting quantum dots (Luminol-R) to mice with induced MPO activity. We selected a lipopolysaccharide (LPS)-induced pulmonary inflammation model because of previous difficulty in using luminol to detect MPO activity in lung tissues. We intravenously (i.v.) injected Luminol-R into mice at 3 h after LPS delivery and then imaged the mice for luminescent signals (Fig. 1a,b) . As compared to luminol-injected mice that had relatively low-level luminescent signals (1.15 × 10 3 ± 0.78 × 10 3 (mean ± s.e.m) photons cm −2 sr −1 s −1 ), mice receiving Luminol-R showed robust luminescent signals (42.4 × 10 3 ± 15 × 10 3 photons cm −2 sr −1 s −1 ) in the lungs. MPO detection by Luminol-R was 37-fold more sensitive than detection by luminol. Longitudinal imaging showed that Luminol-R-emitted luminescence reached its peak at 20 min and gradually declined to a basal level by 180 min (Fig. 1c) .
We also monitored the distribution of quantum dots with fluorescent imaging (Fig. 1d) . Quantum dot-mediated fluorescence was distributed throughout the body. Ex vivo imaging detected fluorescence in the liver, heart, stomach, duodenum, small intestine, spleen, lungs and kidney tissues but not in brain tissue, indicating that quantum dots did not cross the blood-brain barrier. Luminol-R-emitted luminescence was only detectable in the lungs (Fig. 1e) .
CRET improved in vivo detectability of MPO activity To determine whether CRET occurred with quantum dots in a nonconjugated state, we set up in vitro MPO reactions with and without quantum dots and spectrally analyzed the reactions. The MPO reaction with luminol alone produced a luminescence emission peak at 425 nm (Fig. 2a) . In the presence of quantum dots 800, a new luminescence peak at 800 nm was detectable in a quantum dot concentration-dependent fashion, supporting our hypothesis that luminescence energy transfer occurs when the fluorescence acceptor is in a nonconjugated state. CRET also occurred under in vivo conditions. We observed three emission peaks at 445 nm, 625 nm and 800 nm in freshly resected lungs taken from LPSchallenged mice (Fig. 2b) . The 800-nm peak, which comprised 13% of the total luminescent signals emitted from Luminol-R, is the expected emission spectrum of 800-nm-emitting quantum dots. The 625-nm peak was caused by tissue absorption and re-emission of the luminol signal, as it was missing from the in vitro MPO spectral analysis assay.
We also analyzed the emission spectrum under in vivo conditions with an IVIS Spectrum imaging system, which showed that the CRET signal comprised 81% of the total detectable luminescence (Fig. 2c) . When compared with ex vivo imaging that detected strong luminescent signals, in vivo imaging detected only ~7% of the luminescence measured ex vivo (Fig. 2d) . These results indicate that in vivo detection of the luminol-emitted light is dependent predominantly on the red-shifted CRET signal. 
npg t e c h n i c a l r e p o r t s
Peroxidase and chlorination activities of MPO It is well known that MPO shows chlorination and peroxidation activity as a result of activation by hydrogen peroxide. We designed an experiment to dissect the contribution of these activities with respect to luminescent production by MPO. We found much stronger luminescent signals in MPO reactions that contained both sodium chloride and hydrogen peroxide in a manner that was dependent on the concentration of hydrogen peroxide ( Fig. 2e) . At hydrogen peroxide concentrations of 500 µM and 50 µM, the luminescent emissions of the MPO reactions without sodium chloride were 35% and 49%, respectively, compared to the identical reactions with sodium chloride, indicating that chlorination dominated over peroxidation under these conditions (Fig. 2f) .
We further compared the chlorination and peroxidase activities of MPO with those of lactoperoxidase (LPO). Luminescence from the LPO assay was substantially lower than that from the MPO assay (Fig. 2g) . In the presence of sodium chloride, the LPO reaction produced only 30% of the luminescent signals as compared to the MPO reaction.
Luminol-R-mediated luminescence is dependent on MPO activity
We examined the effect of MPO inhibition on Luminol-R-mediated luminescent light emission under both in vitro and in vivo conditions. An inhibition assay with the irreversible MPO inhibitor 4-ABAH showed that 4-ABAH dose-dependently inhibited MPO activity at 0-1,500 nM with a half-maximal inhibitory concentration (IC 50 ) of 41 nM (Fig. 3a,b) . At high concentrations (>1,000 nM), 4-ABAH inhibited more than 90% of the MPO activity. Under in vivo conditions, we found that pretreatment with 4-ABAH attenuated Luminol-R-mediated luminescence in the lungs (Fig. 3c) . Quantification of luminescent signals showed that 4-ABAH treatment before LPS administration suppressed the LPS-induced pulmonary MPO activity by 74% (Fig. 3d) . This inhibition was statistically significant (P < 0.05). Analysis of the lung tissue homogenate showed that 4-ABAH-treated lungs had reduced MPO enzymatic activity compared to LPS-treated positive controls (Fig. 3e) , verifying that the inhibition was irreversible.
The dependence of the Luminol-R-mediated luminescent signal on MPO activity was further supported in an experiment with MPO-deficient mice. In syngeneic wild-type C57BL/6 (Mpo +/+ ) mice, intratracheal LPS challenge remarkably induced MPO activity in the lungs. In contrast, the MPO activity was significantly (P < 0.05) less in LPS-challenged Mpo −/− mice (Fig. 3f,g ). We then investigated the possible role of nitric oxide on luminescence production. Pretreatment with a nonspecific nitric oxide synthase inhibitor, l-NAME, had no impact on the luminescent signal in the lungs of LPS-challenged mice (Fig. 3h) .
Effect of MLN120B on MPO induction
We previously showed that LPS-induced lung injury involves nuclear factor κB (NF-κB) activation and that this induction can be suppressed by MLN120B 12 . Here we investigated whether inhibition of the NF-κB signaling pathway by MLN120B affects MPO activity and hypochlorous acid production during pulmonary inflammation. We pretreated mice with MLN120B (300 mg per kg body weight) and then challenged them intratracheally with LPS. Imaging analysis showed that MLN120B pretreatment markedly attenuated the luminescent signal in the lungs as compared to LPS-treated positive control mice (Fig. 4a) . The inhibition was as much as 70% (Fig. 4b) and was statistically significant (P < 0.01).
We then immunohistochemically analyzed the lung tissues to check whether the inhibition by MLN120B was acting on neutrophil infiltration or inhibition of MPO. Using a neutrophilspecific antibody, Ly-6G, we observed noticeable neutrophil infiltration in LPS-treated lung tissues compared to untreated lungs. MLN120B treatment significantly reduced the infiltration of neutrophils to the lung tissues, resulting in a decrease in MPO activity (Fig. 4c) . These results provide evidence of that the NF-κB signaling pathway is crucial in regulating pulmonary inflammation and MPO production. Detection of MPO activity from tumor metastases It has been shown that some malignant tumors attract neutrophil infiltration during their progression 13 . We investigated whether we could use Luminol-R to detect MPO activity in deep tissue tumor metastases. We established systemic MDA-MB-231-luc2 tumor metastasis through intracardiac injection of tumor cells into NU/NU mice. Bioluminescent imaging of the mice, enabled using the luc2 luciferase gene engineered into these tumor cells, showed the development of multiple metastases on the limbs and mandible and inside the abdominal cavity at 3 weeks after tumor-cell injection (Fig. 5a) . At the sites of tumor metastases, in close proximity to the humerus, tibia and femur, osteolytic lesions were evident by micro-computed tomography (microCT) imaging ( Fig. 5b-d) . After i.v. delivery of Luminol-R to the mice, we were able to detect luminescent signals at all of the (Fig. 5e) , indicating the presence of MPO activity in these lesions. Immunohistochemical analysis showed increased staining of neutrophils and MPO in MDA-MB-231-luc2 tumor metastases (Fig. 5f,g ) as compared with healthy tissues from control NU/NU mice in the same anatomical locations (Fig. 5h,i) .
We further performed three-dimensional bioluminescent imaging of the mice and estimated the depth of each metastatic lesion with a reconstruction algorithm (DLIT) program. We co-registered the three-dimensional bioluminescent images with three-dimensional microCT images to display all metastatic lesions in a referenced anatomical setting (Fig. 5j) . The measured tumor depths ranged from 1.2 mm to 6.8 mm, confirming that Luminol-R-mediated CRET is suitable for monitoring MPO in deep tissue inflammatory foci.
DISCUSSION
Our nanoparticle-based luminescent detection approach relies on a similar energy transfer mechanism as do BRET and CRET, which use conjugation of luminescent enzymes to quantum dots, allowing luminescence to be absorbed and re-emitted by the nanoparticles at a longer wavelength. Recently, fluorescent nanoparticles such as quantum dots have been used as in vivo imaging agents because of their broad absorption spectra, high quantum yields and photostabilities 14, 15 . Their blue-increasing extinction coefficiency allows fluorescent nanoparticles to be excited more efficiently by shorter-wavelength blue light 16 , such as that emitted by luminol, with re-emission of this light in the NIR range. The major finding in this study is that nanoparticles in a nonconjugated form can also effectively convert luminescence to NIR photons. By enabling this photo shift, our nanoparticle-based luminescent detection method allows in vivo assaying of endogenous enzymes such as MPO.
Chronic exposure to large amounts of LPS is reported to be associated with the development and progression of many types of pulmonary diseases, including asthma and COPD 17 . The pathogenesis of COPD is characterized by neutrophil infiltration of pulmonary tissues and elevated concentrations of MPO in bronchoalveolar lavage fluids 18 . MPO is the only enzyme in the body that is known to produce hypochlorous acid, which oxidizes lipids, proteins and DNA 3,4 .
Hypochlorous acid can be detected with luminol because of the light-emitting reaction of these two components. However, the short wavelength of luminol-emitted luminescence limits its application for the detection of deep tissue MPO activity. Using an LPS-induced lung injury model, we demonstrated that quantum dots were able to convert luminol-emitted blue light to NIR photons that were capable of penetrating tissue at depth. Although the efficiency of energy conversion was only ~13%, the detectability of MPO activity in the lung tissues was improved by 37-fold in Luminol-R-injected mice compared to luminol-injected mice. Our study demonstrated that conversion to NIR luminescence is the unequivocal factor for sensitive MPO detection in vivo. MPO production in the lungs during LPS-induced injury correlated with neutrophil infiltration in the lung tissues. In addition, we found direct evidence of elevated amounts of MPO protein in the lung tissues. Using Mpo −/− mice, we demonstrated that the Luminol-R-mediated luminescent signal is dependent on MPO activity. We also ruled out any involvement of nitric oxide in luminescence generation using l-NAME, a nonspecific nitric oxide synthase inhibitor 19 . We then investigated the ability of Luminol-R to monitor the pharmacological inhibition of MPO. 4-ABAH is the most potent MPO inhibitor that functions as a suicide MPO substrate 6 . We demonstrated that 4-ABAH pretreatment significantly attenuated MPO activity in the lungs.
MPO gene expression is under the regulation of a number of transcription factors, including myeloid nuclear factors 1α and 1β 20 and granulocyte colony-stimulating factor 13 . However, there is no evidence of direct involvement of NF-κB in MPO gene regulation. Nevertheless, evidence showed that under inflammatory disease conditions, NF-κB activation is accompanied by an elevation of MPO activity in inflamed tissues. In a previous study of LPS-induced lung injury in Sprague-Dawley rats, pulmonary tissues showed NF-κB activation and elevation of MPO activity 21 . Treatment with penehyclidine hydrochloride resulted in inhibition of the NF-κB pathway, reduction of MPO activity and suppression of inflammatory cell infiltration to the lung tissues. An increase in MPO activity has also been observed under other disease conditions, such as colitis 22 . These studies demonstrated that inhibition of NF-κB activation is associated with 24 . Human monocytes also contain MPO-positive granules. However, they are fewer in number than neutrophils. In addition, MPO expression is lost during differentiation into tissue macrophages 25 . Thus, a substantial contribution of monocytes, macrophages or both to MPO activity during lung injury is unlikely. Previous studies have shown that most malignant tumors contain a substantial number of leukocytic infiltrates that are linked to poor patient prognosis, with increasing evidence showing that neutrophils actively participate in this process 26 . Using a systemic MDA-MB-231-luc2 metastatic model, we showed that Luminol-R successfully visualized tumor metastases of various depths, thus establishing that the nanoparticle-based luminescent detection approach can be used to assess MPO activity in lesions beyond superficial levels. In addition to monitoring pulmonary inflammation and the activity of neutrophils in oncogenesis, it is possible that Luminol-R could be used for the diagnostic detection of other neutrophil-associated inflammatory conditions, such as atherosclerosis, peritonitis, arthritis and sepsis. Clinical application of the nanoparticle-based MPO detection method may become possible if Luminol-R is proven safe for use in humans. Of the two agents used in the Luminol-R formulation, luminol has been used to treat humans with alopecia areata 27 . It can be rapidly cleared from the system without causing toxicity 28 . The development of fluorescent quantum dots for preclinical and clinical applications involves safety considerations. In preclinical tumor-targeting studies, there have been no observations of short-term toxicity of cadmium-containing quantum dots in mice 29, 30 . The long-term toxicity of these particles to both animals and humans remains unknown. Nevertheless, concerns regarding cadmium toxicity have led to the recent development of cadmium-free quantum dots 31 and gold-based nanomaterials 32 . The prospect of applying the nanoparticle-based luminescent detection method in the clinic may draw more research to this area.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Reagents. We obtained bacterial LPS, (from Salmonella abortus-equi), 4-ABAH, l-NAME and LPO from Sigma-Aldrich Chemical Co. (St. Louis, MO), luminol from Biosynth Chemistry & Biology (Itasca, Illinois), QD800 from Life Sciences (Grand Island, NY) and mouse MPO from R&D Systems (Minneapolis, MN).
Animals. We obtained 8-to 10-week-old female BALB/cJ, C57BL/6 and Mpo −/− mice from the Jackson Laboratory (Bar Harbor, Maine) and 8-to 10-week-old female NU/NU mice from Charles River (Wilmington, MA). All animal studies were approved by the Institutional Animal Care and Use Committee at Caliper, Alameda, CA.
Imaging analysis of MPO activity. Acute lung injury was elicited with intratracheal delivery of 50 µl of 10 mg/ml LPS solution to BALB/cJ mice using a 22-gauge intubator. After 3-4 h, mice were i.v. injected with 125 µl of luminol (40 mg/ml) or 137.5 µl of Luminol-R (125 µl of 40 mg/ml luminol mixed with 12.5 µl QD800 (100 pmol)) and imaged in an IVIS Spectrum instrument (Caliper, Alameda, CA) for 5 min with an open filter.
Three-dimensional bioluminescence imaging and mCT co-registration. Mice were i.p. injected with 150 mg per kg body weight luciferin, anesthetized and imaged with narrowband light emission filters (580-640 nm). After optical imaging, the mice were imaged with a Quantum FX µCT system. Threedimensional reconstruction of the optical and µCT images and co-registration of the two were performed with the Living Image4.2 Software.
In vitro MPO assay with Luminol-R. In a 96-well black plate, an MPO activity assay was set up as follows: 80 µl of 0.5 µg/ml MPO in 150 mM NaCl (pH 7.4) was added to each well and then 80 µl of 2 mM luminol and 1 µl of 8 µM QD800 were added. Eighty microliters of 150 µM hydrogen peroxide solution was added to initiate the reaction. The plate was immediately assayed with an IVIS Spectrum instrument with a 5-min exposure time. In another experiment, the reaction mixture was set up with either 2 nM of LPO or 2 nM of MPO in a final volume of 240 µl. The reactions were assayed as described above. To study the effect of MPO inhibition by 4-ABAH, 10 µl of the 4-ABAH stock solutions were added to the reaction mix before the addition of hydrogen peroxide to obtain final 4-ABAH concentrations of 0, 6.25, 12.5, 25, 0.50, 100, 150, 200, 250, 500, 1,000 and 1,500 nM. Luminescent signals from each well were quantified using the Living Image software.
